Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

Mohammad Bosaeed; Ebrahim Mahmoud; Ahmad Alharbi; Hadeel Altayib; Hawra Albayat; Faisal Alharbi; Khalid Ghalilah; Abdulmajid Al Arfaj; Jumana AlJishi; Abdullatif Alarfaj; Hajar Alqahtani; Badriah M. Almutairi; Manar Almaghaslah; Nawaf M. Alyahya; Abdullah Bawazir; Saud AlEisa; Abdulrahman Alsaedy; Abderrezak Bouchama; Malak Alharbi; Majid AlShamrani; Sameera Al Johani; Majed Aljeraisy; Mohammed Alzahrani; Abdulhakeem O. Althaqafi; Hassan Almarhabi; Athari Alotaibi; Nasser Alqahtani; Yaseen M. Arabi; Omar S. Aldibasi; Ahmad Alaskar

Infectious Diseases and Therapy (2021) - Comments
pubmed: 34319552 doi: 10.1007/s40121-021-00496-6 issn: 2193-8229 issn: 2193-6382

Mohammad Bosaeed, Ebrahim Mahmoud, Ahmad Alharbi, Hadeel Altayib, Hawra Albayat, Faisal Alharbi, Khalid Ghalilah, Abdulmajid Al Arfaj, Jumana AlJishi, Abdullatif Alarfaj, Hajar Alqahtani, Badriah M. Almutairi, Manar Almaghaslah, Nawaf M. Alyahya, Abdullah Bawazir, Saud AlEisa, Abdulrahman Alsaedy, Abderrezak Bouchama, Malak Alharbi, Majid AlShamrani

Go to article
Go to preprint

Springer Science and Business Media LLC